menu
    • menu
    [{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"bb21217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"2Seventy Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Undisclosed"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BB21217","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"2Seventy Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Undisclosed"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SC-DARIC33","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Undisclosed"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Undisclosed"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Undisclosed"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"Idecabtagene Vicleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0.28999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"MegaTAL mRNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"1","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"MegaTAL mRNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ 2Seventy Bio","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ JW Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ JW Therapeutics"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ Novo Nordisk"}]

    Find Clinical Drug Pipeline Developments & Deals by 2Seventy Bio

    Menu

    2Seventy Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $286.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

                            Details : Through the acquisition, BMS will gain full control of Abecma (idecabtagene vicleucel), which is indicated for the treatment of relapsed/refractory multiple myeloma.

                            Product Name : Abecma

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $286.0 million

                            March 10, 2025

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $286.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel,Fludarabine Phosphate,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb and 2seventy bio Update on KarMMa-9 Trial of Abecma in Myeloma

                            Details : Abecma (idecabtagene vicleucel) is a CAR T cell therapy which binds to BCMA on the surface of multiple myeloma cells. It is being evaluated for newly diagnosed multiple myeloma.

                            Product Name : Abecma

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 25, 2024

                            Lead Product(s) : Idecabtagene Vicleucel,Fludarabine Phosphate,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Novo Nordisk

                            Deal Size : $40.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            2seventy bio Sells Hemophilia A Candidate and MegaTAL Technology to Novo Nordisk for $40M

                            Details : Novo has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 26, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Novo Nordisk

                            Deal Size : $40.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Abecma for Triple-Class Exposed Myeloma After Two Prior Therapies

                            Details : Abecma (idecabtagene vicleucel) is a CAR T cell therapy for multiple myeloma, approved for treating triple-class exposed relapsed or refractory patients.

                            Product Name : Abecma

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 05, 2024

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Regeneron Forms Cell Medicines with Acquisition Of 2seventy Bio

                            Details : Regeneron will have full development and commercialization rights to its pipeline of investigational immune cell therapies, including Abecma (idecabtagene vicleucel).

                            Product Name : Abecma

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $5.0 million

                            January 30, 2024

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for R...

                            Details : Abecma (idecabtagene vicleucel) is a BCMA directed CAR-T cell immunotherapy, for patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and...

                            Product Name : Abecma

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 11, 2023

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicle...

                            Details : Abecma (idecabtagene vicleucel) is a CAR T cell therapy that recognizes and binds to BCMA on the surface of multiple myeloma cells, for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM).

                            Product Name : Abecma

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 20, 2023

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Ver...

                            Details : Idecabtagene Vicleucel is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 21, 2023

                            Lead Product(s) : Idecabtagene Vicleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC-DARIC33

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

                            Details : SC-DARIC33 is a investigational drug-regulated CAR T cell (DARIC) Therapy and T cells activater, which is investigated for the treatment for Acute Myeloid Leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 14, 2023

                            Lead Product(s) : SC-DARIC33

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            2Seventy Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : $40.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclin...

                            Details : The collaboration is focused on an in vivo gene editing treatment for hemophilia A by utilizing 2seventy bio’s megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit, or insert genetic components.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $5.0 million

                            May 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : $40.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth